Clinical Trial Update: Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sintilimab combined with regorafenib and hepatic arterial infusion chemotherapy (HAIC) in patients with colorectal liver metastasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Liver Metastasis

Drugs mentioned

• HAIC (hepatic artery infusion chemotherapy)
• Regorafenib (regorafenib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Colorectal Cancer, Liver Metastasis | Phase 2 | Status: UNKNOWN